Clinical Trials Directory

Trials / Completed

CompletedNCT06881316

Caffeine vs. Carbohydrate Mouth Rinsing in Soccer

Caffeine vs. Carbohydrate Mouth Rinsing in Soccer: Effects on Passing Performance and Psychophysiological Responses in Youth Players

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Tokat Gaziosmanpasa University · Academic / Other
Sex
Male
Age
14 Years – 16 Years
Healthy volunteers
Accepted

Summary

The present study evaluated the influence of carbohydrate mouth-rinsing (CHO-MR), caffeine mouth-rinsing (CAF-MR), and control-substance mouth rinses on Loughborough soccer passing test (LSPT) performance. The study participants were involved in a randomized, double-blind, repeated-measures design that employed four sessions (familiarization, CHOMR, CAFMR, and CONT) over ten days at a testing facility. Participants took part in six test sessions 72 hours apart. In the CHO group, 6% w/v glucose solution was used. In the CAFF group, 6% w/v glucose solution was used. CONT group, only exercise was performed without any condition.

Detailed description

Participants were involved in a randomized, double-blind, repeated-measures design that employed four sessions (familiarization, LSPTCHO, LSPTCAFF, and LSPTCONT) over ten days at a testing facility. The initial session was an orientation, allowing participants to acclimate to the LSPT protocol and provide written informed consent. This session used water as a mouth rinse. Anthropometric data were also collected. Before the LSPT, participants completed 15-minute standardized warm-up sections, including jogging, sprinting, and integrating soccer-specific actions. The participants were asked to complete the LSPT at any time. During the tests, participants were blinded to the test scores. The following three sessions were test trials conducted between 15.00 h and 17.00 h at 32°C and 40% humidity. The participants performed the LSPT 72 h apart, LSPTCHO (6% w/v glucose solution), LSPTCAFF (1.2% w/v caffeine solution), and LSPTCONT conditions. Caffeine and CHO solutions were prepared in an equivalent saccharin base to ensure indistinguishability within the Falcon Sterile Tube and agitated for 30 seconds on a vortex mixer. Participants were instructed to avoid intense activity 24 hours before testing, observe a 2-hour fast before sessions, and abstain from caffeinated products on test days. All the test sessions were performed at 32°C and 40% humidity.

Conditions

Interventions

TypeNameDescription
OTHERCaffeineParticipants' solutions were prepared in separate Falcon Sterile Tubes: LSPTCAFF (1.2% w/v caffeine solution, Nature's Supreme). An MRI was performed before the LSPT. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The caffeine solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before LSPT and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz.
OTHERCHOParticipants' solutions were prepared in separate Falcon Sterile Tubes: LSPTCHO (6% w/ v glucose solution, Protein Ocean, Turkey) An MRI was performed prior to LSPT. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The CHO solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before LSPT and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz.
OTHERControlFor the control condition, no supplements were taken and only exercise was performed.

Timeline

Start date
2025-02-10
Primary completion
2025-02-25
Completion
2025-02-26
First posted
2025-03-18
Last updated
2025-03-18

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06881316. Inclusion in this directory is not an endorsement.